RM-493 Treatment Trial in Proopiomelanocortin (POMC) Deficient Patients
NCT02507492
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
10
Enrollment
OTHER
Sponsor class
Conditions
Homozygous or Compound Heterozygous POMC, LEPR or PCSK1 Gene Mutation
Interventions
DRUG:
RM-493
Sponsor
Charite University, Berlin, Germany